Navigation Links
Myelogenous in Medical News

Cepheid Announces European Release of Improved Test for BCR-ABL Chromosomal Translocation Associated With Chronic Myelogenous Leukemia (CML)

Oncology Test Further Highlights Broad Market Applicability of GeneXpert System SUNNYVALE, Calif., June 17 /PRNewswire-FirstCall/ -- Cepheid (Nasdaq: CPHD ) today announced the release of its improved Xpert(R) BCR-ABL Monitor test to be marketed as a CE IVD product under the Euro...

Prescription Copay Assistance for Patients taking Gleevec or Tasigna for Philadelphia chromosome-positive Chronic Myelogenous Leukemia (Ph+ CML)

Novartis Pharmaceuticals Corporation offers a prescription copay assistance program for Ph+ CML (Chronic Myelogenous Leukemia or Chronic Myeloid Leukemia) patients through the My CML Circle Copay Assistance Program ( www.mycmlcircle.com ). East Hanover, NJ (PRWEB) Febru...

Vion Pharmaceuticals Announces Presentation of Data from Phase III Trial of Cloretazine(R) (VNP40101M) and Cytarabine in Relapsed Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that data from the Phase III trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in combination with cytarabine in patients with first relapse of acute myelogenous leukemia ...

Pharmion and MethylGene Present Favorable Clinical Data From Combination MGCD0103/Vidaza(R) Study in Myelodysplastic Syndromes and Acute Myelogenous Leukemia at The 49th American Society of Hematology (ASH) Meeting

* Recommended Phase II Dose of MGCD0103 Determined as 90 mg * 53% of Patients Treated with 90 mg Dose Achieved a Clinical Response * Patients with Responses Experienced a 66% Reduction in the Risk of Death Compared to Non-responders ATLANTA, Dec. 10 /PRNewswire-...

Dasatinib, Nilotinib show strong early results as frontline therapy for chronic myelogenous leukemia

ATLANTA - Two drugs approved for use as second line therapy for chronic myelogenous leukemia are showing promising results as frontline therapy for newly diagnosed patients in two clinical trials, research teams led by scientists at The University of Texas M. D. Anderson Cancer Center report at th...

Eliminating Influence of Hyperactive Genes That Help Regulate Cell Development Shows Potential as Additional Target Therapy for Chronic Myelogenous Leukemia

Researchers at Cincinnati Children's Zero In on Rac1, Rac2 Genes as Molecular Targets CINCINNATI, Nov. 12 /PRNewswire/ -- In a study published in the Nov. 13 issue of Cancer Cell, researchers at Cincinnati Children's Hospital Medical Center reported that they have d...

The Leukemia & Lymphoma Society Hosts Workshop On Weighing Treatment Options For Chronic Myelogenous Leukemia

Free, Interactive Workshop Features CML Expert, Jorge Cortes, M.D. WHITE PLAINS, N.Y., Sept. 6 /PRNewswire/ -- Jorge Cortes, M.D., an expert on leukemia, will discuss novel treatment approaches for chronic myelogenous leukemia (CML) in a free telephone workshop entitled CML: A Model in Canc...

Chronic Myelogenous Leukemia (CML) Has An Answer Now!

Another plant extract called Forskolin has been found to be helpful in inhibiting the growth of chronic myelogenous leukemia (CML) cells in cultures and mice by up to 90 percent.// Forskolin is prepared from the root of the plant coleus forskohlii, a native of India that is used as an alternativ...

Finding key to cancer drug Gleevec's limitations

...ressing disease in which too many of certain white blood cells are made in the bone marrow. It is also called chronic granulocytic leukemia or chronic myelogenous leukemia. An estimated 5,050 men and women will be diagnosed with chronic myeloid leukemia in 2009, and 470 will die of the disease, according to the ...

Janet Rowley, MD, A Researcher Funded by The Leukemia & Lymphoma Society, Receives Presidential Medal of Freedom

...work developing a tool to more precisely diagnose genetic subtypes of acute myelogenous leukemia (AML) so that more appropriate individualized treatment can be app... Dr. Rowley showed that the Philadelphia Chromosome associated with chronic myelogenous leukemia (CML) was an abnormal translocation of two chromosomes. Her discov...
Myelogenous in Medical Technology

Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia

FRAZER, Pa., June 19 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH ) today announced results from a pivotal clinical trial of lestaurtinib (CEP-701) in patients with relapsed acute myelogenous leukemia (AML) expressing FLT3 activating mutations. The study was designed to show th...

Vion Pharmaceuticals Announces Presentation of Interim Data from Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Acute Myelogenous Leukemia at the ASCO(R) Annual Meeting

NEW HAVEN, Conn., June 2 /PRNewswire-FirstCall/ -- VION PHARMACEUTICALS, INC. (Nasdaq: VION ) today announced that interim data from the pivotal Phase II trial of its lead anticancer agent Cloretazine(R) (VNP40101M) in elderly patients with de novo poor-risk acute myelogenous leukemia (AML) h...

Pharmion and MethylGene Announce U.S. Orphan Drug Designation Granted for MGCD0103 for the Treatment of Acute Myelogenous Leukemia

BOULDER, Colo. and MONTREAL, Feb. 14 /PRNewswire-FirstCall/ -- Pharmion Corporation (Nasdaq: PHRM ) and MethylGene Inc. (TSX: MYG) today announced that the U.S. Food and Drug Administration (FDA) has designated the Companies' histone deacetylase (HDAC) inhibitor, MGCD0103, as an Orphan Drug f...

Pharmion and MethylGene Announce Orphan Drug Designation Granted by the European Medicines Agency (EMEA) for MGCD0103 for the Treatment of Acute Myelogenous Leukemia

BOULDER, Colo., and MONTREAL, Feb. 11 /PRNewswire-FirstCall/ -- Pharmion (Nasdaq: PHRM ) and MethylGene Inc. (TSX: MYG) today announced that the European Medicines Agency (EMEA) and the European Commission (EC) designated MGCD0103, a histone deacetylase (HDAC) inhibitor, as an Orphan Medicina...

Dasatinib Shows High Early Response Rate as First Treatment for Chronic Myelogenous Leukemia, M. D. Anderson Researchers Report

CHICAGO, June 2, 2007 - An established second-line drug for chronic myelogenous leukemia has high response rates when given to newly diagnosed patients as their first therapy for the disease, according to early results from a Phase II clinical trial at The University of Texas M. D. Anderson Cance...

Bayer Announces Leukine(R) Data Presentations at 45th American Society of Clinical Oncology (ASCO) Annual Meeting

...e(R) (sargramostim) is the only growth factor approved in the U.S. for use following induction chemotherapy in older adults (older than 55) with acute myelogenous leukemia (AML) to shorten the time to neutrophil recovery and reduce the incidence of severe and life-threatening infections and infections resulting ...

Medarex Announces Allowance of Investigational New Drug Application for Wholly-Owned Fully Human Anti-CXCR4 Antibody, MDX-1338

... -Clinical study planned for relapsed / refractory acute myelogenous leukemia- PRINCETON, N.J., May 27 /PRNewswire-FirstCall/ -- Medarex, I...Administration (FDA) for MDX-1338, for the treatment of patients with acute myelogenous leukemia (AML). MDX-1338 is a fully human antibody that targets CXCR4, a ch...

University of California Los Angeles Selects Velos eResearch

...t approved treatment that attacks cancer at its genetic root; Gleevec , a once-a-day pill that targets a common form of adult leukemia called chronic myelogenous leukemia, or CML; Sprycel , also a pill that targets CML; Tarceva , a targeted lung cancer drug; and Avastin , a targeted drug for colorectal c...

Medarex Announces Preclinical Data from Multiple Research Programs Demonstrating Anti-Tumor Activity in Cancer

...inding of CXCR4 to its ligand, CXCL12, thereby inhibiting chemotaxis and migration responses. In addition, MDX-1338 also reduced tumor growth in acute myelogenous leukemia and lymphoma xenograft models. Efficacy of MDX-1110, an anti-Fucosyl-GM1 antibody in a SCLC tumor model (Abstract #838) Fucosyl-GM1...

Research Teams at J. Craig Venter Institute and Ludwig Institute for Cancer Research Uncover New Chromosomal Alterations in Cancer Using Transcriptome Sequencing Approach

...on of many kinds of cancers. The discovery of the best known gene fusion, BCR-ABL, led to the development of Gleevec(R) for the treatment of chronic myelogenous leukemia and other cancers. In this proof of concept study the researchers focused on the transcriptome, a subset of genes in the genome that cod...
Myelogenous in Medical Definition

Hematopathology

...eukemia is the proliferation of too many mature blood cells , and is called that because it is a chronic process clinically. Examples are chronic myelogenous leukemia and chronic lymphocytic leukemia . Acute leukemia is the proliferation of too many immature blood cells, called myeloblasts , which have...
Myelogenous in Medical Dictionary

Leukemia

...healthcare professionals and consumers about adult myelogenous leukemia (AML) Offers information about tre...ype of acute leukemia in adults. ... Acute myelogenous leukemia (AML) cancer is also as acute myelo...owly progressing) ... Leukemia is categorized as myelogenous or lymphocytic, which denotes the ... Hutchins...

Cml

... Chronic myelogenous (or myeloid) leukemia ( CML ), also known as ch...ormation summary about the treatment of chronic myelogenous leukemia . ... Most people with CML have a gene...e ... Offers resources for concerning Chronic myelogenous Leukemia including news, personal experiences, co...

Acute myelogenous leukemia

...te myeloid leukemia (AML), also known as acute myelogenous leukemia , is a cancer of the myeloid line of b...Hodgkin's disease and myeloma. ... Have acute myelogenous leukemia with very high white cell counts. ... Advances in the treatment of acute myelogenous leukemia (AML) have ... Acute ...
Myelogenous in Biological News

GUMC discovery highlights new direction for drug discovery

...s in use now that work against fusion proteins inhibit a single protein to stop intrinsic enzymatic activity; one example is Gleevec, used for chronic myelogenous leukemia (CML). The Ewing's sarcoma fusion protein, known as EWS-FLI1, lacks enzymatic activity, "and this difference is why our work is significant,"...

Small molecules block cancer gene

...rch showed that it also was important in breast, lung and prostate cancers as well as multiple myeloma (a cancer affect blood-forming cells) and acute myelogenous leukemia. Stat3 also plays a role in chronic virus infections, asthma, psoriasis and inflammatory bowel disease all areas that Tweardy and his co...

Washington University scientists first to sequence genome of cancer patient

...decoded the complete DNA of a cancer patient and traced her disease - acute myelogenous leukemia - to its genetic roots. A large research team at the Genome Sequen...elped identify the targeted drug Gleevec as a promising therapy for chronic myelogenous leukemia. Druker, the director of the Oregon Health & Science University Ca...

Meyskens honored with AACR-Prevent Cancer Foundation award

... cellular changes that may develop into cervical cancer in some women. Additionally, he promoted the idea that retinol could be used to affect chronic myelogenous leukemia (CML). Meyskens has re-examined the scientific basis for the etiology of melanoma. Based on 15 years of detailed laboratory work, he prop...

TGen and Washington University researchers discover new approach to treating endometrial cancer

...netic signature of each patient's tumor, a strategy that has been effective in multiple cancer types, including breast cancer, lung cancer and chronic myelogenous leukemia. ...

FDA approves Vidaza label expansion

...d that Vidaza is the only agent that extends survival in MDS (myelodysplastic syndromes) patients. Vidaza was also shown to delay progression to acute myelogenous leukemia (AML) in patients with MDS. Roughly 30 percent of patients diagnosed with MDS will progress to AML. "We are very encouraged by the Vida...

OHSU turns innovations into commercial opportunities at record pace

... recognized for his role in the clinical development of Gleevec (Imatinib), the first molecular-targeted medication to prove effective against chronic myelogenous leukemia (CML). Heinrich was the first to identify mutations in platelet-derived growth factor receptors (PDGFR) as the cause of gastrointestinal stro...

St. Jude finds factors that accelerate resistance to targeted therapy in lymphoblastic leukemia

...s Research Hospital provide strong evidence for why the targeted therapy drug, imatinib, or Gleevec, which has revolutionized the treatment of chronic myelogenous leukemia, (CML) is often unable to prevent relapse of a particularly aggressive form of acute lymphoblastic leukemia (ALL). Targeted therapy drugs are...

Distinguishing friend from foe in the battle against cancer

...mycin is mediated by the survival factor NF-kB. Rapamycin, like the pharmaceutical superstar Gleevec, which revolutionized the treatment of chronic myelogenous leukemia, is a so-called signal transduction inhibitor or STI, a small molecule that stifles inappropriate growth signals sent by mutant proteins in c...

'Tribbles' protein implicated in common and aggressive form of leukemia

... Researchers at the University of Pennsylvania School of Medicine have identified a new protein associated with acute myelogenous leukemia (AML). Several lines of evidence point to a protein called Tribbles, named after the furry creatures that took over the starship Enterprise i...
Myelogenous in Biological Technology

The Leukemia & Lymphoma Society and Provid Pharmaceuticals Announce Collaboration on Treatment for Acute Myelogenous Leukemia

WHITE PLAINS, N.Y., June 10 /PRNewswire/ -- Provid Pharmaceuticals, Inc. and The Leukemia & Lymphoma Society (LLS) today jointly announced the execution of a research agreement to advance the development of a treatment for acute myelogenous leukemia. Under the arrangement, LLS has contracted...

Cell Therapeutics Exercises Its Option to Sell Interest in Zevalin Joint Venture to Spectrum Pharmaceuticals for $18 Million

...of rituximab. The risk of hematologic toxicity correlated with the degree of bone marrow involvement prior to Zevalin therapy. Myelodysplasia or acute myelogenous leukemia was observed in 2 percent of patients (8 to 34 months after treatment). Zevalin should only be used by health care professionals qualified by...

Vion Pharmaceuticals to Present Survival Data on Laromustine at ASH Annual Meeting

...Poor Risk Acute myelogenous Leukemia" Date: Saturday, December 6 ...1M). Vion Co-Sponsors Seminar on Acute myelogenous Leukemia in Elderly Patients The Compan...ith previously untreated de novo poor-risk acute myelogenous leukemia. Clinical trials of Onrigin(TM) (laromust...

Gleevec Receives FDA Priority Review as First Therapy to Reduce Recurrence of Gastrointestinal Stromal Tumors After Surgery

...c for the treatment of GIST in the adjuvant setting would add to its eight current indications, which include Philadelphia chromosome-positive chronic myelogenous leukemia (Ph+ CML) and five other rare diseases. Novartis also has a therapy for the treatment of carcinoid tumors and acromegaly and multiple treatme...

Biopure Announces 2008 Third Quarter Financial Results

...d Drug Administration (FDA) for proposed clinical trials. The trial in discussion between Biopure and the FDA is a small trial for patients with acute myelogenous leukemia (AML) who refuse transfusion with blood components and therefore cannot currently undergo induction chemotherapy, which depletes oxygen-carry...

SGX - Lilly Merger Offer Receives Positive Opinions From Proxy Advisory Firms

...he MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human canc...

SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008

...he MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic myelogenous Leukemia, or CML. Our drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human canc...

SuperGen Reports 2008 Second Quarter Financial Results

...he presentations are included below: -- SGI-1776, our lead pre-clinical PIM kinase inhibitor, was found to cause tumor regression in acute myelogenous leukemia (AML) xenograft models (Abstract No. 4974). In an oral presentation entitled, "A potent small molecule PIM kinase inhibitor wi...

Genzyme Reports Strong Second-Quarter Growth

...cts that the labeling for Clolar(R) (clofarabine) will be expanded by the middle of next year to include its use in treating adult patients with acute myelogenous leukemia. The company plans to file supplemental marketing applications this year to broaden Clolar's indication. -- Genzyme expects to launch Mozob...

Lilly to Acquire SGX Pharmaceuticals

...he MET receptor tyrosine kinase, an enzyme implicated in a broad array of cancers, and the BCR-ABL tyrosine kinase enzyme for the treatment of Chronic myelogenous Leukemia, or CML. Its drug discovery activities are focused on a portfolio of other protein and enzyme targets that have been implicated in human canc...
Myelogenous in Biological Products

Chicken Anti-DCTD (dCMP deaminase) Polyclonal Antibody, Unconjugated from GenWay Biotech, Inc.

Description:...= dUMP + NH 3 . SUBUNIT: Homohexamer. SIMILARITY: Belongs to the Diseases: Benign Tumor; Leukemia; Escherichia Coli; Lymphadenopathy; Fungi; Lymphoma; myelogenous Leukemia; Pregnancy; Herpesviruses; Adenocarcinoma; Liver Cancer; Lung Cancer; Lung Tumor; Lung Diseases; Herpes Simplex Virus; Epidermoid Carcinoma; ...
Company:GenWay Biotech, Inc.
Other Tags
(Date:3/4/2015)... Sonoma, CA (PRWEB) March 04, 2015 ... which supports American military service members during and after ... for a Cause,” will increase awareness through advertising, social ... raise funds for the patriotic organization through a special ... Cabernet Sauvignon wines from March through May 2015. ...
(Date:3/4/2015)... 04, 2015 Staff Sgt Shilo Harris ... in Iraq, tells you about the pain and struggle ... Chiropractic care from the Patriot Project and through that ... is what Harris said in a recent interview, , ... I feel more calm, I'm sleeping better, and many ...
(Date:3/4/2015)... CA (PRWEB) March 04, 2015 ... have been selected by Chase Brexton Health Care, ... announced today. , Chase Brexton provides comprehensive primary ... than 30,000 patients across seven clinics in the ... adopters of electronic medical records, the organization has ...
(Date:3/4/2015)... 04, 2015 Follow us on ... driven by the increasing incidence of CNS disorders, aging ... late stage drugs. The unmet medical needs for diagnosing ... potential in the market. Presently, there exists an urgent ... the limitations of current generation drugs. Companies are therefore ...
(Date:3/4/2015)... Jose, California (PRWEB) March 04, 2015 ... as chemical preparations for enhancing the appearance of the ... using a wide variety of therapeutic agents to achieve ... lifestyle products in a society obsessed with physical beauty, ... reliant on the production and sales of cosmetics. Growth ...
Breaking Medicine News(10 mins):Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 2Health News:Plungerhead Partners with the Boot Campaign to Benefit US Military Community 3Health News:Decorated Veterans Endorse “Halos for Heroes” an Indiegogo campaign to Help Wounded Military Heal at Home 2Health News:Decorated Veterans Endorse “Halos for Heroes” an Indiegogo campaign to Help Wounded Military Heal at Home 3Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 2Health News:Chase Brexton Selects i2i Systems Population Health Management Solutions to Demonstrate HEDIS Quality Outcomes to Maryland’s Health Plans 3Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Rising Incidence of CNS Disorders & a Promising Global Drug Pipeline Drive the CNS Therapeutics Market, According to a New Report by Global Industry Analysts, Inc. 4Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 2Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 3Health News:Rising Demand for Anti-Aging & Skincare Cosmeceuticals to Drive the Global Cosmetic Chemicals Market, According to a New Report by Global Industry Analysts, Inc. 4
(Date:3/4/2015)... --Research and Markets ( http://www.researchandmarkets.com/research/48tj8z/global_biometrics ) ... Biometrics Market Forecast and Opportunities, 2020" report ... biometric authentication systems is projected to grow at ... The driving forces for this highly competitive ... and constant development in technology. In 2014, government ...
(Date:3/3/2015)... March 3, 2015 Cryoport, Inc. ... advanced cryogenic logistics solutions for the life ... cells, cell lines, clinical research organizations, vaccine ... announced the expansion of its relationship with ... ("Fred Hutch") Clinical Research Division with the ...
(Date:3/2/2015)... SAN JOSE, Calif. , March 2, 2015 ... ), the leading developer of human interface solutions, ... ID technology that is designed to enable rapid ... Synaptics Natural ID™ module for gaming is a ... and ODMs the ability to quickly integrate fingerprint ...
Breaking Biology News(10 mins):Global Biometrics Market Forecast and Opportunities, 2020 2Global Biometrics Market Forecast and Opportunities, 2020 3Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 2Cryoport, Inc. Expands Support of Fred Hutchinson Cancer Research Center's Clinical Research Division 3Synaptics Unveils New Fingerprint ID Solution for Gamers 2Synaptics Unveils New Fingerprint ID Solution for Gamers 3
Other Contents